A GARP investor would be drawn to the 0.9 PEG Forward, which implies growth is being acquired at a discount relative to its projected expansion. The 22.70% ROE demonstrates efficient capital deployment, while a 5.80% ROIC, though more modest, remains positive and suggests incremental returns above capital costs. A Piotroski F-Score of 6 indicates fundamentally sound operations without distress signals, and the 10.40% operating margin confirms operating leverage is emerging. Combine that with a conservative 8.30% Debt/Equity ratio and an 8.8 Altman Z-Score, and you have a company that can fund growth internally while maintaining solvency strength—exactly the profile institutional investors seek when rotating into profitable mid-cap healthcare growth.